Industry / Spain
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
Court Ruling Could Harm Generics Industry
February 2008 | Industry NewsSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
A ruling by the Barcelona High Court upholding the patent for US-based drugmaker Eli Lilly 's schizophrenia drug Zyprexa (olanzapine) could have far-reaching implications for the pharmaceutical industry, according to the Spain's generics association, AESGP.